| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
Cancer during the COVID-19 pandemic: did we shout loudly enough and did anyone listen? A lasting legacy for nations
|
Price, Pat
|
|
|
152 |
C |
p. 243-244
|
artikel
|
| 2 |
Chemotherapy-induced ovarian failure in young women with early breast cancer: Prospective analysis of four randomised neoadjuvant/adjuvant breast cancer trials
|
Furlanetto, Jenny
|
|
|
152 |
C |
p. 193-203
|
artikel
|
| 3 |
Clinical characteristics and therapy response in unresectable melanoma patients stage IIIB-IIID with in-transit and satellite metastases
|
Zaremba, Anne
|
|
|
152 |
C |
p. 139-154
|
artikel
|
| 4 |
Clinical effectiveness of olaparib monotherapy in germline BRCA-mutated, HER2-negative metastatic breast cancer in a real-world setting: phase IIIb LUCY interim analysis
|
Gelmon, Karen A.
|
|
|
152 |
C |
p. 68-77
|
artikel
|
| 5 |
Corrigendum to “The use of ‘added benefit’ to determine the price of new anti-cancer drugs in France, 2004–2017” [Eur J Canc 145 (2021) 11–18]
|
Rodwin, Marc A.
|
|
|
152 |
C |
p. 259-261
|
artikel
|
| 6 |
Economic impact of avoidable cancer deaths caused by diagnostic delay during the COVID-19 pandemic: A national population-based modelling study in England, UK
|
Gheorghe, Adrian
|
|
|
152 |
C |
p. 233-242
|
artikel
|
| 7 |
Effectiveness of first-line abiraterone versus enzalutamide among patients ≥80 years of age with metastatic castration-resistant prostate cancer: A retrospective propensity score–weighted comparative cohort study
|
Soleimani, Maryam
|
|
|
152 |
C |
p. 215-222
|
artikel
|
| 8 |
Epidemiology of cutaneous melanoma and keratinocyte cancer in white populations 1943–2036
|
Garbe, Claus
|
|
|
152 |
C |
p. 18-25
|
artikel
|
| 9 |
European trends in breast cancer mortality, 1980–2017 and predictions to 2025
|
Wojtyla, Cezary
|
|
|
152 |
C |
p. 4-17
|
artikel
|
| 10 |
Health-related quality of life in Dutch adult survivors of childhood cancer: A nation-wide cohort study
|
van Erp, L.M.E.
|
|
|
152 |
C |
p. 204-214
|
artikel
|
| 11 |
Immune checkpoint inhibitors in treatment of soft-tissue sarcoma: A systematic review and meta-analysis
|
Saerens, Michael
|
|
|
152 |
C |
p. 165-182
|
artikel
|
| 12 |
Male fertility during and after immune checkpoint inhibitor therapy: A cross-sectional pilot study
|
Salzmann, Martin
|
|
|
152 |
C |
p. 41-48
|
artikel
|
| 13 |
Neoadjuvant immunotherapy is reshaping cancer management across multiple tumour types: The future is now!
|
Maio, Michele
|
|
|
152 |
C |
p. 155-164
|
artikel
|
| 14 |
Nose in malignant mesothelioma—Prediction of response to immune checkpoint inhibitor treatment
|
Disselhorst, Maria J.
|
|
|
152 |
C |
p. 60-67
|
artikel
|
| 15 |
Plasma androgen receptor and response to adapted and standard docetaxel regimen in castration-resistant prostate cancer: A multicenter biomarker study
|
Conteduca, Vincenza
|
|
|
152 |
C |
p. 49-59
|
artikel
|
| 16 |
Preference for the fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection in patients with HER2-positive early breast cancer (PHranceSCa): A randomised, open-label phase II study
|
O'Shaughnessy, Joyce
|
|
|
152 |
C |
p. 223-232
|
artikel
|
| 17 |
Prognostic factors of metastatic neuroendocrine carcinoma under first-line treatment with platinum etoposide with a focus on NEC score and Rb expression: Results from the multicentre RBNEC study of the Groupe d’Etude des Tumeurs Endocrines (GTE) and the ENDOCAN-RENATEN network
|
Hadoux, Julien
|
|
|
152 |
C |
p. 100-115
|
artikel
|
| 18 |
Prognostic value of the 6-gene OncoMasTR test in hormone receptor–positive HER2-negative early-stage breast cancer: Comparative analysis with standard clinicopathological factors
|
Lynch, Seodhna M.
|
|
|
152 |
C |
p. 78-89
|
artikel
|
| 19 |
Prospective Phase II trial of radiation therapy in localised non-gastric marginal zone lymphoma with prospective evaluation of autoimmunity and Helicobacter pylori status: TROG 05.02/ALLG NHL15
|
MacManus, Michael P.
|
|
|
152 |
C |
p. 129-138
|
artikel
|
| 20 |
Quality of life in patients with BRAF-mutant melanoma receiving the combination encorafenib plus binimetinib: Results from a multicentre, open-label, randomised, phase III study (COLUMBUS)
|
Gogas, Helen
|
|
|
152 |
C |
p. 116-128
|
artikel
|
| 21 |
Randomised phase 2 study comparing the efficacy and safety of the oral tyrosine kinase inhibitor nintedanib with single agent ifosfamide in patients with advanced, inoperable, metastatic soft tissue sarcoma after failure of first-line chemotherapy: EORTC-1506-STBSG “ANITA”
|
Schöffski, Patrick
|
|
|
152 |
C |
p. 26-40
|
artikel
|
| 22 |
Rare use of patient-reported outcomes in childhood cancer clinical trials – a systematic review of clinical trial registries
|
Riedl, David
|
|
|
152 |
C |
p. 90-99
|
artikel
|
| 23 |
Re: A systematic review and meta-analysis: The effect of active cancer treatment on severity of COVID-19
|
Zou, Caifeng
|
|
|
152 |
C |
p. 245-247
|
artikel
|
| 24 |
Re: ‘Can we replace adjuvant chemotherapy with surveillance for stage IA-C immature ovarian teratomas of any grade? An international multicenter analysis’
|
Lockley, Michelle
|
|
|
152 |
C |
p. 255-256
|
artikel
|
| 25 |
Re: Carvedilol blocks neural regulation of breast cancer progression in vivo and is associated with reduced breast cancer mortality in patients
|
De Sanctis, Rita
|
|
|
152 |
C |
p. 250-251
|
artikel
|
| 26 |
Response to letter entitled: Re: A systematic review and meta-analysis: The effect of active cancer treatment on severity of COVID-19
|
Yekedüz, Emre
|
|
|
152 |
C |
p. 248-249
|
artikel
|
| 27 |
Response to letter entitled: Re: Can we replace adjuvant chemotherapy with surveillance for stage IA-C immature ovarian teratomas of any grade? An international multicenter analysis
|
Bergamini, Alice
|
|
|
152 |
C |
p. 257-258
|
artikel
|
| 28 |
Response to the letter Re: Carvedilol blocks neural regulation of breast cancer progression in vivo and is associated with reduced breast cancer mortality in patients
|
Botteri, Edoardo
|
|
|
152 |
C |
p. 252-254
|
artikel
|
| 29 |
The incidence, treatment and survival of patients with rare types of rectal malignancies in the Netherlands: A population-based study between 1989 and 2018
|
van Rees, Jan M.
|
|
|
152 |
C |
p. 183-192
|
artikel
|
| 30 |
Treatment with encorafenib and cetuximab of a non–anti–epidermal growth factor receptor–naive patient for BRAF V600E–mutated metastatic colon cancer
|
El-khoury, Reem
|
|
|
152 |
C |
p. 1-3
|
artikel
|
Tijdschrift beschrijving